Biopharma licensing deals dominated last year as drug developer venture capital and IPO activity was muted, per a new JPMorgan and DealForma report reviewed by Axios Pro exclusively.
The big picture: The proliferation of licensing deals is fueled by Big Pharma's need to identify promising new drugs and fill dwindling pipelines.
